GAMMA Investing LLC Acquires Shares of 467 Encompass Health Co. (NYSE:EHC)

GAMMA Investing LLC acquired a new stake in shares of Encompass Health Co. (NYSE:EHC) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 467 shares of the company’s stock, valued at approximately $33,000.

Several other institutional investors and hedge funds have also bought and sold shares of EHC. Invesco Ltd. lifted its position in shares of Encompass Health by 22.3% during the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock worth $266,914,000 after acquiring an additional 724,544 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of Encompass Health by 6.4% during the third quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock worth $381,226,000 after acquiring an additional 342,512 shares in the last quarter. California Public Employees Retirement System raised its position in shares of Encompass Health by 160.5% in the fourth quarter. California Public Employees Retirement System now owns 515,717 shares of the company’s stock worth $34,409,000 after buying an additional 317,730 shares in the last quarter. Lisanti Capital Growth LLC purchased a new stake in shares of Encompass Health in the third quarter worth $10,410,000. Finally, FMR LLC raised its position in shares of Encompass Health by 11.6% in the third quarter. FMR LLC now owns 1,374,755 shares of the company’s stock worth $92,329,000 after buying an additional 142,633 shares in the last quarter. 97.25% of the stock is owned by institutional investors.

Encompass Health Trading Down 0.3 %

NYSE EHC opened at $83.21 on Monday. The stock’s 50-day simple moving average is $79.15 and its two-hundred day simple moving average is $71.64. Encompass Health Co. has a twelve month low of $57.55 and a twelve month high of $85.84. The company has a market capitalization of $8.33 billion, a price-to-earnings ratio of 22.49, a PEG ratio of 1.30 and a beta of 0.92. The company has a quick ratio of 1.28, a current ratio of 1.37 and a debt-to-equity ratio of 1.14.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same period last year, the firm earned $0.88 earnings per share. The company’s revenue for the quarter was up 13.4% compared to the same quarter last year. Research analysts forecast that Encompass Health Co. will post 4.1 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Monday, July 1st. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.72%. Encompass Health’s dividend payout ratio (DPR) is currently 16.22%.

Analysts Set New Price Targets

EHC has been the topic of a number of recent analyst reports. Barclays increased their price objective on Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Truist Financial increased their price objective on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $83.00 price objective on shares of Encompass Health in a research report on Friday, February 9th. Raymond James restated a “strong-buy” rating and set a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Finally, Mizuho raised their price target on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Encompass Health has an average rating of “Buy” and a consensus target price of $90.29.

Insider Activity

In other news, CEO Mark J. Tarr sold 44,976 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.